# Skye Bioscience, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Skye Bioscience, Inc.). ## Overview Skye Bioscience, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing GPCR-modulating therapies for obesity, overweight, and related conditions. Its lead program, nimacimab, is a subcutaneous injectable antibody targeting the CB1 receptor, and the company operates through a small corporate structure with subsidiaries in the United States, Australia, and Canada. ## Products & services • Nimacimab clinical development for obesity and overweight • GPCR-targeted antibody drug discovery • Preclinical and nonclinical pipeline research • Clinical trial execution through third-party partners • Manufacturing and CMC development for biologics - **Lead clinical program** (100%) — Development of nimacimab, a CB1-targeting antibody for obesity and related metabolic conditions. - **Discovery and preclinical pipeline** (0%) — Early-stage research on additional GPCR-modulating molecules and related assets. - **Clinical development services** (0%) — Use of CROs, investigative sites, and consultants to run trials and support regulatory advancement. - **Manufacturing and CMC development** (0%) — Third-party manufacturing and process development for nimacimab and future biologics. - Nimacimab clinical development for obesity and overweight - GPCR-targeted antibody drug discovery - Preclinical and nonclinical pipeline research - Clinical trial execution through third-party partners - Manufacturing and CMC development for biologics ## Customers Skye Bioscience does not yet commercialize products, so its near-term counterparties are primarily clinical trial sites, contract research organizations, manufacturers, and scientific consultants rather than end-market buyers. If approved, nimacimab would be sold to physicians, obesity specialists, and healthcare systems treating patients with obesity and overweight. The company may also pursue collaboration partners that can help fund development or provide commercial infrastructure. - **Clinical research partners** (primary) — CROs, investigators, and trial sites that execute nimacimab studies and generate clinical data. - **Manufacturing partners** (primary) — Third-party biologics manufacturers and consultants that support drug substance and drug product supply. - **Future prescribers and care providers** (secondary) — Physicians and obesity-treatment providers who would prescribe nimacimab if approved. - **Potential collaboration partners** (secondary) — Pharmaceutical or biotech partners that may provide funding, development support, or commercialization reach. - CROs and investigative sites running clinical trials - Biologics manufacturers producing clinical and future commercial supply - Physicians and obesity specialists as future prescribers - Healthcare systems and clinics treating metabolic disease - Potential licensing or collaboration partners ## Geography Skye Bioscience is headquartered in San Diego, California and also maintains administrative office space in San Francisco. Its operating footprint is international at the corporate level through subsidiaries in the United States, Australia, and Canada, while clinical and manufacturing activities are largely outsourced to third parties. Because the company is pre-revenue, geography matters mainly through where it conducts research, trials, and future commercialization rather than through current sales mix. - Headquartered in San Diego, California - Administrative office space in San Francisco, California - Subsidiaries in the United States, Australia, and Canada - Clinical and manufacturing work is outsourced across partner locations - No disclosed revenue by country because the company has no revenue ## Strategy Skye Bioscience’s strategy centers on advancing nimacimab through clinical development and building evidence for its use in obesity and related metabolic conditions. The company also seeks to expand its pipeline of GPCR-based molecules while relying on third-party partners for trials, manufacturing, and eventual commercialization. This approach keeps capital focused on science and development, but it also makes execution and partner selection central to the business model. - **Advance nimacimab through clinical trials** (short-term) — Clinical proof-of-concept is the main value driver for a pre-commercial biotech. - **Secure manufacturing and development partners** (short-term) — The company depends on external providers for clinical supply and trial execution. - **Expand the GPCR-based pipeline** (medium-term) — A broader pipeline can diversify scientific risk beyond a single lead asset. - **Prepare for future commercialization or partnering** (medium-term) — Approval would require sales, distribution, and market access capabilities. - Advance nimacimab through clinical development - Build data in obesity and related metabolic indications - Use third parties for trials, manufacturing, and future sales - Develop additional GPCR-modulating pipeline assets - Pursue collaborations that can support funding and commercialization ## Risks Skye Bioscience faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, dependence on external partners, and the need for substantial additional financing before any product revenue. Its lead asset concentration means setbacks in nimacimab could materially affect the company, while competition, intellectual property protection, and regulatory requirements also remain central risks. - **Clinical development failure for nimacimab** [critical] — The company’s value is concentrated in a single lead program and clinical outcomes are uncertain. - **Dependence on third-party manufacturers and CROs** [high] — Skye lacks internal commercial and manufacturing infrastructure, creating execution and supply risk. - **Need for additional financing** [high] — Development-stage biotech programs consume cash before any product revenue is generated. - **Competition from larger biopharma companies** [high] — Competitors may have more resources, broader pipelines, and faster development capabilities. - **Intellectual property protection** [medium] — The company’s ability to defend its proprietary molecules and methods affects long-term value. - No product revenue until regulatory approval and commercialization - Clinical trial results may fail to support efficacy or safety claims - Heavy dependence on third-party CROs and manufacturers - Need for additional financing to fund development - Competition from larger biotech and pharma companies ## Accounting The most important accounting judgments are clinical accruals, especially estimating percentage-of-completion for CRO and site costs, and the fair value of assets acquired in prior transactions. Because the company is pre-revenue, reported results are driven by research and development expense timing, stock-based compensation, and any gains or losses from asset sales or contingencies. Investors should also watch estimates for legal contingencies and other liabilities, which can materially affect period-to-period comparability. - **Accrued research and development expenses** — Can shift expense recognition between quarters - **Fair value of acquired assets** — Can influence intangible asset balances and future impairment risk - **Legal contingencies** — May create one-time gains, losses, or reserve changes - **Stock-based compensation** — Affects reported G&A and R&D costs - Clinical accrual estimates affect R&D expense timing - Fair value of acquired assets can change reported balances - Stock-based compensation affects operating expense - Legal contingencies may create volatile liabilities - No revenue recognition issues yet because the company is pre-revenue --- *Last updated: 2026-04-29T04:59:00.539086+00:00*